Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACVBP
- Development stage
- Unknown
- Lead developer
- Groupe d'Étude des Lymphomes de l'Adulte
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
ACVBP is an intensive combination chemotherapy regimen used primarily for the treatment of aggressive non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). The acronym stands for its component drugs: doxorubicin (Adriamycin), cyclophosphamide, vindesine, bleomycin, and prednisone. In some protocols, rituximab is added to form the R-ACVBP or ACVBP-R regimen. The mechanism of action involves multiple cytotoxic agents with different targets and mechanisms—doxorubicin intercalates DNA and inhibits topoisomerase II; cyclophosphamide alkylates DNA; vindesine disrupts microtubule formation; bleomycin induces DNA strand breaks; prednisone is a corticosteroid with lympholytic effects. This multi-agent approach aims to maximize tumor cell kill and reduce resistance. ACVBP has been shown in clinical trials to improve event-free survival and overall survival compared to standard CHOP therapy in certain high-risk patient populations but at the cost of increased toxicity[1][3][4].
- Other names
- ACVBP regimenAdriamycin-Cytoxan-Vindesine-Bleomycin-Prednisone regimen
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on ACVBP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACVBP.